AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26912492 — intervention group
Group type: EXPERIMENTAL
Intervention: High-normal VitB12 concentration
Number of subjects: 100
Study 26912492 — intervention group
Group type: COMPARATOR
Intervention: Low-normal VitB12 concentration
Number of subjects: 100
Study 26913587 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 166
Study 26913587 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher side effect expectations
Number of subjects: 166
Study 26913587 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative necessity-concern balance
Number of subjects: 166
Study 26913693 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat bone marrow aspiration after induction therapy
Number of subjects: 289
Study 26913693 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay in bone marrow aspiration (≥7 days)
Number of subjects: 289
Study 26913693 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD-positive at original aspiration vs MRD-negative at repeat aspiration
Number of subjects: 289
Study 26913697 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine + rituximab (BR) induction
Number of subjects: 34
Study 26913697 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance lenalidomide (5-10 mg/d for 12 cycles)
Number of subjects: 34
Study 26913697 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine + rituximab (BR) induction without maintenance therapy
Number of subjects: 34
Study 26913756 — intervention group
Group type: EXPERIMENTAL
Intervention: Disaccharidase activity (lactase, sucrase, maltase, palatinase)
Number of subjects: 61
Study 26913756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin and lactoferrin levels
Number of subjects: 61
Study 26913756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal permeability (rhamnose/lactulose test)
Number of subjects: 61
Study 26913756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal inflammation on intestinal biopsy
Number of subjects: 61
Study 26915009 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Protein Solution (APS)
Number of subjects: 11
Study 26915641 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized and family-based lifestyle intervention
Number of subjects: 506
Study 26915641 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 506
Study 26915709 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control
Number of subjects: 987
Study 26915709 — intervention group
Group type: COMPARATOR
Intervention: Less tight control
Number of subjects: 987
Study 26916450 — intervention group
Group type: COMPARATOR
Intervention: Primary care
Number of subjects: 17374
Study 26916450 — intervention group
Group type: COMPARATOR
Intervention: Specialist care
Number of subjects: 17374
Study 26916481 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) implantation
Number of subjects: 1305
Study 26916481 — intervention group
Group type: COMPARATOR
Intervention: BVS-specific implantation strategy
Number of subjects: 1305
Study 26916565 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient rehabilitation after NPM SAH
Number of subjects: 66
Study 26916565 — intervention group
Group type: COMPARATOR
Intervention: NPM SAH without rehabilitation
Number of subjects: 66
Study 26916582 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe-brachial index (TBI) measurement in men
Number of subjects: 73
Study 26916582 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe-brachial index (TBI) measurement in women
Number of subjects: 73
Study 26916582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI) measurement
Number of subjects: 73
Study 26916582 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TBI with published reference values
Number of subjects: 73
Study 26916582 — intervention group
Group type: COMPARATOR
Intervention: Gender comparison of TBI
Number of subjects: 73
Study 26916582 — intervention group
Group type: COMPARATOR
Intervention: Variability of TBI in women
Number of subjects: 73
Study 26916841 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention strategies for adolescent HIV prevention including family meetings, communal parenting, and building efficacy around parent-adolescent communication.
Number of subjects: 82
Study 26917438 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical debridement and systemic antibiotics
Number of subjects: 60
Study 26917486 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel/Depot
Number of subjects: 273
Study 26917615 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued anticoagulation after negative D-dimer
Number of subjects: 0
Study 26917615 — intervention group
Group type: EXPERIMENTAL
Intervention: Remained without anticoagulation despite positive D-dimer
Number of subjects: 0
Study 26917615 — intervention group
Group type: EXPERIMENTAL
Intervention: New isolated PE recurrences
Number of subjects: 0
Study 26917617 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 0
Study 26918032 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreign-born blacks (FBB)
Number of subjects: 1035
Study 26918032 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 1035
Study 26918032 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1035
Study 26918124 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antithrombotic drugs
Number of subjects: 4700000
Study 26918192 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral fat measurement via dual-energy X-ray absorptiometry
Number of subjects: 71
Study 26918192 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine forced expiratory volume in 1 s
Number of subjects: 71
Study 26918192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sniff maximum pressure
Number of subjects: 71
Study 26918192 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean overnight arterial oxygen saturation
Number of subjects: 71
Study 26918192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory response to 15% O2 breathing
Number of subjects: 71
Study 26918192 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels
Number of subjects: 71
Study 26919403 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ADT
Number of subjects: 180
Study 26919403 — intervention group
Group type: COMPARATOR
Intervention: Intermittent ADT
Number of subjects: 180
Study 26919403 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA3 score < level of quantification
Number of subjects: 180
Study 26919403 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline metastatic disease
Number of subjects: 180
Study 26919403 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone level
Number of subjects: 180
Study 26919994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb muscle strength (LMS)
Number of subjects: 345
Study 26920463 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicutaneous immunotherapy using the Viaskin patch, dosage and duration not available
Number of subjects: 0
Study 26920463 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26920495 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed <0.5 m/s (slowest walkers)
Number of subjects: 8039
Study 26920495 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed 0.5-0.83 m/s (slow walkers)
Number of subjects: 8039
Study 26920495 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed >0.83 m/s (normal walkers)
Number of subjects: 8039
Study 26920495 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 0.2 m/s decrease in gait speed
Number of subjects: 8039
Study 26920495 — intervention group
Group type: COMPARATOR
Intervention: Slowest walkers compared to normal walkers
Number of subjects: 8039
Study 26920668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 142
Study 26920728 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC stroke risk score
Number of subjects: 15701
Study 26920728 — intervention group
Group type: COMPARATOR
Intervention: CHA2DS2-VASc score
Number of subjects: 15701
Study 26920731 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum trans fatty acids (TFAs)
Number of subjects: 1364
Study 26920731 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum trans 16:1n7
Number of subjects: 1364
Study 26920731 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum trans 18:1
Number of subjects: 1364
Study 26920731 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans 16:1n7 and trans 18:1
Number of subjects: 1364
Study 26920731 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ADMA levels
Number of subjects: 1364
Study 26921148 — intervention group
Group type: EXPERIMENTAL
Intervention: New prediction model for 60-day hospital mortality
Number of subjects: 3746
Study 26921148 — intervention group
Group type: EXPERIMENTAL
Intervention: New prediction model for 60-day ICU mortality
Number of subjects: 3746
Study 26921148 — intervention group
Group type: COMPARATOR
Intervention: APACHE II score alone
Number of subjects: 3746
Study 26921281 — intervention group
Group type: EXPERIMENTAL
Intervention: JetStream XC atherectomy device
Number of subjects: 29
Study 26921281 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive balloon angioplasty
Number of subjects: 29
Study 26921281 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolic filter protection
Number of subjects: 29
Study 26921281 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-procedure-related adverse events
Number of subjects: 29
Study 26921281 — intervention group
Group type: EXPERIMENTAL
Intervention: Postatherectomy stent integrity
Number of subjects: 29
Study 26921283 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental supply of sips of alcohol
Number of subjects: 1729
Study 26922148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (increased quantities of energy, protein, fat, essential fatty acids and vitamin A), n=24
Number of subjects: 46
Study 26922148 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard nutrition), n=22
Number of subjects: 46
Study 26922278 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard education
Number of subjects: 71
Study 26922278 — intervention group
Group type: EXPERIMENTAL
Intervention: No education
Number of subjects: 71
Study 26922278 — intervention group
Group type: COMPARATOR
Intervention: Candidates for LVAD treatment
Number of subjects: 71
Study 26922498 — intervention group
Group type: EXPERIMENTAL
Intervention: NOWAPI(®)
Number of subjects: 22
Study 26922498 — intervention group
Group type: COMPARATOR
Intervention: Polygraphy
Number of subjects: 22
Study 26923436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) 400 mg/day with median starting ribavirin (RBV) dose of 800 mg (IQR: 400-1200)
Number of subjects: 1789
Study 26923436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) 400 mg/day
Number of subjects: 1789
Study 26923436 — intervention group
Group type: EXPERIMENTAL
Intervention: RBV-free regimens
Number of subjects: 1789
Study 26923627 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest ODI tertile (severe OSA)
Number of subjects: 302
Study 26923627 — intervention group
Group type: COMPARATOR
Intervention: First ODI tertile (mild OSA)
Number of subjects: 302
Study 26923627 — intervention group
Group type: COMPARATOR
Intervention: Second ODI tertile (moderate OSA)
Number of subjects: 302
Study 26923772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vimentin-positive CTCs
Number of subjects: 93
Study 26923772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki67-positive CTCs
Number of subjects: 93
Study 26923925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) delivered by bachelor-level lay providers (BLPs)
Number of subjects: 112
Study 26923925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) delivered by PhD-level expert providers (PLPs)
Number of subjects: 112
Study 26923925 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study 26924501 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDS
Number of subjects: 0
Study 26924633 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder (BD)
Number of subjects: 39
Study 26924633 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 39
Study 26924680 — intervention group
Group type: EXPERIMENTAL
Intervention: DDC gene common genetic polymorphisms (haplotypes)
Number of subjects: 120
Study 26925252 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA discontinuation
Number of subjects: 220
Study 26925252 — intervention group
Group type: COMPARATOR
Intervention: ADA continuation
Number of subjects: 220
Study 26926297 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary indices of GAG fragmentation in septic shock patients
Number of subjects: 125
Study 26926297 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary indices of GAG fragmentation using dimethylmethylene blue assay in septic shock patients
Number of subjects: 125
Study 26926297 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary indices of GAG fragmentation in ARDS patients
Number of subjects: 125
Study 26926297 — intervention group
Group type: COMPARATOR
Intervention: Nonseptic ICU control (surgical ICU patients)
Number of subjects: 125
Study 26926629 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 123
Study 26926644 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin intravenous dosing regimens (5 mg/kg for ≤32 weeks PMA, 7 mg/kg for 32 to 40 weeks PMA, 9 mg/kg for >40 to 60 weeks PMA) administered every 8 hours
Number of subjects: 62
Study 26926644 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 62
Study 26926676 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone in patients with RS ≤ 11
Number of subjects: 3198
Study 26926676 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy in patients with RS > 25
Number of subjects: 3198
Study 26926676 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy in patients with RS 12 to 25
Number of subjects: 3198
Study 26927285 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide-based diuretic regimen
Number of subjects: 3
Study 26927672 — intervention group
Group type: EXPERIMENTAL
Intervention: Octanoic acid (OA) administered in doses ranging from 8 to 128 mg/kg
Number of subjects: 0
Study 26927672 — intervention group
Group type: EXPERIMENTAL
Intervention: Octanoic acid (OA)
Number of subjects: 0
Study 26928166 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia practice (specific intervention details not provided)
Number of subjects: 0
Study 26928166 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study 26928328 — intervention group
Group type: EXPERIMENTAL
Intervention: VTX-2337
Number of subjects: 13
Study 26929095 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPlan 1.0 (GPs' intervention group)
Number of subjects: 426
Study 26929095 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPlan 1.0 (researchers' intervention group)
Number of subjects: 426
Study 26929095 — intervention group
Group type: COMPARATOR
Intervention: Usual care (waiting-list control group)
Number of subjects: 426
Study 26929286 — intervention group
Group type: EXPERIMENTAL
Intervention: Amended classification system for open abdomen
Number of subjects: 542
Study 26929418 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter regimen using currently available TB drugs
Number of subjects: 0
Study 26929418 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline-containing regimens (all-oral and shortened version)
Number of subjects: 0
Study 26929418 — intervention group
Group type: COMPARATOR
Intervention: WHO-recommended standard of care
Number of subjects: 0
Study 26929648 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg IV every 14 days) and Erlotinib (150 mg oral daily)
Number of subjects: 44
Study 26929777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg daily
Number of subjects: 50
Study 26929777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26930146 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV4 vaccine (1-3 doses)
Number of subjects: 2091
Study 26930208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumovax (PPV23) immunization
Number of subjects: 0
Study 26930527 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 arm (930 mg EPA/750 mg DHA + 50 mg/d sertraline)
Number of subjects: 122
Study 26930527 — intervention group
Group type: COMPARATOR
Intervention: Sertraline plus placebo arm
Number of subjects: 122
Study 26930627 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir (day 0: 6,000 mg; day 1 to day 9: 2,400 mg/d)
Number of subjects: 126
Study 26930634 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) patients
Number of subjects: 538
Study 26930634 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher apnea-hypopnea index (AHI)
Number of subjects: 538
Study 26930634 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of PlGF
Number of subjects: 538
Study 26930634 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-OSA patients)
Number of subjects: 538
Study 26931117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 1109
Study 26931143 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese mothers
Number of subjects: 331
Study 26931143 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mothers
Number of subjects: 331
Study 26931143 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight and/or obese mothers
Number of subjects: 331
Study 26931143 — intervention group
Group type: COMPARATOR
Intervention: Healthy normal weight controls
Number of subjects: 331
Study 26931156 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy with or without preceding thrombolysis
Number of subjects: 28
Study 26931475 — intervention group
Group type: EXPERIMENTAL
Intervention: Infused angiotensin II (LJPC-501)
Number of subjects: 0
Study 26931738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention for hypertension
Number of subjects: 0
Study 26932146 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF 240 mg BID
Number of subjects: 229
Study 26932146 — intervention group
Group type: COMPARATOR
Intervention: PBO for 2 years followed by DMF 240 mg BID for 4 years
Number of subjects: 229
Study 26932276 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d)
Number of subjects: 406
Study 26932276 — intervention group
Group type: COMPARATOR
Intervention: Nonaspirin
Number of subjects: 406
Study 26932848 — intervention group
Group type: EXPERIMENTAL
Intervention: Group phone-based weight loss intervention
Number of subjects: 186
Study 26933082 — intervention group
Group type: COMPARATOR
Intervention: Acute Ischemic Stroke (AIS) patients
Number of subjects: 29
Study 26933082 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ST-segment-elevation acute coronary syndrome (NSTE-ACS) patients
Number of subjects: 29
Study 26933421 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001
Number of subjects: 0
Study 26933421 — intervention group
Group type: COMPARATOR
Intervention: Platinum doublets
Number of subjects: 0
Study 26933422 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1 inhibitor) and RRx-001 (experimental anticancer agent)
Number of subjects: 1
Study 26933507 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8848 (inhalation dosing)
Number of subjects: 0
Study 26934062 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone (extended-release oral formulation and long-acting injectable once-monthly paliperidone palmitate)
Number of subjects: 0
Study 26934062 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone (monotherapy or adjunctively with antidepressants or mood stabilizers)
Number of subjects: 0
Study 26934141 — intervention group
Group type: EXPERIMENTAL
Intervention: FLIO (Fluorescence Lifetime Imaging Ophthalmoscopy)
Number of subjects: 16
Study 26934345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab therapy
Number of subjects: 100
Study 26934345 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy
Number of subjects: 100
Study 26934345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab/Nivolumab combination
Number of subjects: 100
Study 26934345 — intervention group
Group type: EXPERIMENTAL
Intervention: T-VEC therapy
Number of subjects: 100
Study 26934750 — intervention group
Group type: EXPERIMENTAL
Intervention: Anflu® vaccine (2013-14 formulation: H1N1, H3N2, BYAM)
Number of subjects: 182
Study 26935225 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasonography (POCUS)
Number of subjects: 103
Study 26936878 — intervention group
Group type: EXPERIMENTAL
Intervention: Double pumping
Number of subjects: 62
Study 26936878 — intervention group
Group type: COMPARATOR
Intervention: Single pumping
Number of subjects: 62
Study 26936878 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressing 500 mL/day by day 10
Number of subjects: 62
Study 26936878 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast pump comfort (best)
Number of subjects: 62
Study 26936878 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast pump comfort (middle)
Number of subjects: 62
Study 26936878 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast pump comfort (worst)
Number of subjects: 62
Study 26936878 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of episodes of 'breast feeding'
Number of subjects: 62
Study 26936878 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of complete daily records
Number of subjects: 62
Study 26936878 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of double versus single pumping
Number of subjects: 62
Study 26937680 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond lenticule extraction (FLEx)
Number of subjects: 41
Study 26937680 — intervention group
Group type: COMPARATOR
Intervention: Small-incision lenticule extraction (SMILE)
Number of subjects: 41
Study 26937681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear analysis of respiratory biosignals (Largest Lyapunov Exponent, Detrended Fluctuation Analysis, Approximate Entropy) and linear analysis from Oxygen saturation for predicting Apnea-Hypopnea Index (AHI).
Number of subjects: 135